The Globe and Mail reports in its Thursday edition that menopause specialists are concerned about how Canadian patients will be affected by Pfizer's decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the United States. The Globe's Kristy Kirkup and Chris Hannay write that physicians say they fear patients will have to contend with the ramifications of Pfizer's decision to discontinue Premarin cream and tablets in Canada, prescribed to those navigating menopause symptoms. Existing inventory is expected to last until next year. Premarin was first developed and approved in Canada in 1941 and Pfizer manufactures the global supply of the active ingredient in Brandon, Man. Pfizer first notified Health Canada on Nov. 3 that it would stop supplying Premarin products. The cream is being discontinued immediately and pills will be available while inventory lasts. Pfizer said Premarin products were "commercially unsustainable" in Canada. Obstetrician-gynecologist Jen Gunter in her blog that Pfizer's decision should concern all Canadians. "This isn't just about Premarin," she wrote. "Every Canadian who cares about access to medications need to be engaged and speak up."
© 2026 Canjex Publishing Ltd. All rights reserved.